PA
HQL

Parallel Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Parallel Advisors’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,001
Closed -$15.5K – 3675
2025
Q3 		$15.5K Sell
1,001
-3,828
-79% -$52.4K ﹤0.01% 2377
2025
Q2 		$61.9K Hold
4,829
– – ﹤0.01% 1604
2025
Q1 		$61.3K Sell
4,829
-1,001
-17% -$13.6K ﹤0.01% 1514
2024
Q4 		$76.5K Hold
5,830
– – ﹤0.01% 1404
2024
Q3 		$87.9K Hold
5,830
– – ﹤0.01% 1327
2024
Q2 		$82.6K Sell
5,830
-4,429
-43% -$59.9K ﹤0.01% 1265
2024
Q1 		$140K Buy
10,259
+171
+2% +$2.37K ﹤0.01% 1020
2023
Q4 		$136K Hold
10,088
– – ﹤0.01% 971
2023
Q3 		$126K Buy
10,088
+82
+0.8% +$1.08K ﹤0.01% 981
2023
Q2 		$135K Buy
10,006
+71
+0.7% +$980 ﹤0.01% 945
2023
Q1 		$138K Buy
9,935
+75
+0.8% +$1.07K ﹤0.01% 914
2022
Q4 		$140K Buy
9,860
+39
+0.4% +$565 0.01% 858
2022
Q3 		$134K Hold
9,821
– – 0.01% 840
2022
Q2 		$140K Hold
9,821
– – 0.01% 831
2022
Q1 		$162K Hold
9,821
– – 0.01% 800
2021
Q4 		$189K Sell
9,821
-1,250
-11% -$25.2K 0.01% 773
2021
Q3 		$230K Hold
11,071
– – 0.01% 666
2021
Q2 		$237K Hold
11,071
– – 0.01% 620
2021
Q1 		$218K Buy
11,071
+764
+7% +$15.7K 0.01% 610
2020
Q4 		$204K Hold
10,307
– – 0.01% 582
2020
Q3 		$181K Hold
10,307
– – 0.01% 595
2020
Q2 		$185K Buy
10,307
+2,227
+28% +$38.2K 0.01% 563
2020
Q1 		$121K Hold
8,080
– – 0.01% 613
2019
Q4 		$141K Hold
8,080
– – 0.01% 635
2019
Q3 		$122K Hold
8,080
– – 0.01% 657
2019
Q2 		$136K Sell
8,080
-1,250
-13% -$20.6K 0.01% 566
2019
Q1 		$160K Hold
9,330
– – 0.02% 475
2018
Q4 		$140K Sell
9,330
-2,205
-19% -$38.8K 0.02% 449
2018
Q3 		$236K Buy
11,535
+4,207
+57% +$83.7K 0.03% 351
2018
Q2 		$137K Hold
7,328
– – 0.02% 460
2018
Q1 		$141K Hold
7,328
– – 0.02% 411
2017
Q4 		$144K Hold
7,328
– – 0.02% 392
2017
Q3 		$141K Buy
7,328
+4,828
+193% +$103K 0.02% 390
2017
Q2 		$54K Hold
2,500
– – 0.01% 663
2017
Q1 		$51K Hold
2,500
– – 0.01% 641
2016
Q4 		$42K Buy
+2,500
New +$43.9K 0.01% 640

Other funds holding HQL

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Parallel Advisors's HQL Position: Q4 2025 in Review

Parallel Advisors sold out of abrdn Life Sciences Investors (HQL) in Q4 2025, closing a stake of 1,001 shares — an estimated $15.5K sold.

Parallel Advisors first reported a position in HQL in Q4 2016 and held it in 36 quarters. The position peaked at $237K in Q2 2021. 73 funds tracked by Wall St. Rank hold HQL as of Q4 2025.

  • Parallel Advisors reported no remaining abrdn Life Sciences Investors position as of Q4 2025 after selling out during the quarter.
  • Parallel Advisors sold 1,001 abrdn Life Sciences Investors shares in Q4 2025, an estimated $15.5K.
  • Parallel Advisors first reported a position in abrdn Life Sciences Investors in Q4 2016 and held it in 36 quarters.
  • Parallel Advisors's abrdn Life Sciences Investors position peaked at $237K in Q2 2021.
  • 73 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q4 2025.

Based on Parallel Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.